Ally Bridge Group NY LLC Has $2.35 Million Stock Holdings in aTyr Pharma, Inc. $ATYR

Key Points

• Ally Bridge Group NY LLC increased its stake in aTyr Pharma by 11% during the first quarter, owning a total of 777,020 shares valued at approximately $2.35 million.
• Wall Street analysts maintain a consensus rating of "Buy" for aTyr Pharma, with an average price target of $23.25, despite mixed ratings from various firms.
• aTyr Pharma's current market price is $5.65, with a significant increase noted in its 50-day moving average and a strong institutional ownership of 61.72%.

Ally Bridge Group NY LLC raised its holdings in aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) by 11.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 777,020 shares of the company's stock after purchasing an additional 77,290 shares during the quarter. aTyr Pharma makes up about 2.1% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 16th largest position. Ally Bridge Group NY LLC owned approximately 0.87% of aTyr Pharma worth $2,347,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Erste Asset Management GmbH bought a new position in aTyr Pharma in the 1st quarter valued at $1,812,000. Dimensional Fund Advisors LP bought a new position in aTyr Pharma in the 4th quarter valued at $881,000. Bank of America Corp DE bought a new position in aTyr Pharma in the 4th quarter valued at $330,000. Jane Street Group LLC bought a new position in aTyr Pharma in the 4th quarter valued at $720,000. Finally, Millennium Management LLC bought a new position in aTyr Pharma in the 4th quarter valued at $1,332,000. Institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ATYR shares. Wells Fargo & Company lifted their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, June 20th. Wall Street Zen lowered shares of aTyr Pharma from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective on shares of aTyr Pharma in a report on Wednesday, June 4th. Finally, Jefferies Financial Group increased their price target on aTyr Pharma from $9.00 to $17.00 and gave the stock a "buy" rating in a report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $23.25.

aTyr Pharma Stock Performance

ATYR traded up $0.14 during trading hours on Friday, reaching $5.61. The company's stock had a trading volume of 3,928,278 shares, compared to its average volume of 3,970,087. The company's 50-day moving average is $5.34 and its 200-day moving average is $4.33. The firm has a market cap of $549.71 million, a PE ratio of -7.01 and a beta of 1.01. aTyr Pharma, Inc. has a 52 week low of $1.67 and a 52 week high of $7.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, equities analysts forecast that aTyr Pharma, Inc. will post -0.91 EPS for the current year.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.